KIMS Becomes First Centre In East India To Be Certified For Impella Cardiac Device
KIMS has been certified as the center for Impella Ventricular Support Systems for use during Cardiogenic Shock & High-Risk PCI.
The ImpellaR System is a miniature rotating motor that is inserted inside the ventricle (LV or RV). The Impella pump actively pulls blood out of the ventricle into the aorta or pulmonary artery to increase cardiac output and reduce the workload on the ventricle. The Impella® Ventricular Support Systems have been approved for two separate indications for use: High-Risk PCI and Cardiogenic Shock.
1. High-Risk PCI: The Impella 2.5® and Impella CP® Systems are temporary (≤ 6 hours) ventricular support devices indicated for use during high-risk percutaneous coronary interventions (PCI) performed in elective or urgent, hemodynamically stable patients with severe coronary artery disease, when a heart team, including a cardiac surgeon, has determined high-risk PCI is the appropriate therapeutic option. Use of the Impella 2.5 and Impella CP Systems in these patients may prevent hemodynamic instability, which is resulted from repeat episodes of reversible myocardial ischemia that occur during planned temporary coronary occlusions and may reduce peri- and post-procedural adverse events.
2. Cardiogenic Shock: The Impella 2.5®, Impella CP®, Impella 5.0®, and Impella LD® Catheters, in conjunction with the Automated Impella Controller™ (collectively, “Impella® System Therapy”), are temporary ventricular support devices intended for short term use (≤ 4 days for the Impella 2.5 and Impella CP, and ≤ 14 days for the Impella 5.0 and Impella LD) and indicated for the treatment of ongoing cardiogenic shock that occurs immediately (< 48 hours) following acute myocardial infarction or open heart surgery or in the setting of cardiomyopathy, including peripartum cardiomyopathy, or myocarditis as a result of isolated left ventricular failure that is not responsive to optimal medical management and conventional treatment measures (including volume loading and use of pressors and inotropes, with or without IABP).
The intent of Impella System Therapy is to reduce ventricular work and to provide the circulatory support necessary to allow heart recovery and early assessment of residual myocardial function.
The Heart Team at KIMS comprising Dr Anupam Jena, Dr Ashok Kumar Badamali, Dr. Subashis Mishra, Dr. A Sharda, & Dr. Chandan Kumar Mohapatra recently completed the online training given by the Impella team. The training sessions were attended by the entire Heart Team of KIMS including Cardiologists, Cardiac surgeons and Cardiac anaesthetists, ICU Nurses, Cath lab technicians and Perfusionist. Following the training, they were certified to implant and manage Impella at KIMS and thus KIMS is the first centre in East India to be certified for Impella Cardiac device.